STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

MAIA Biotechnology insider Vlad Vitoc increases MAIA share holdings

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

MAIA Biotechnology CEO share purchases were reported by Vlad Vitoc, who serves as Chief Executive Officer, Director and 10% owner of MAIA Biotechnology, Inc. (MAIA). On 11/21/2025, he bought 1,800 shares of common stock at a weighted average price of $0.92 per share, and on 11/24/2025 he bought an additional 10,000 shares at a price of $0.9891 per share.

Following these transactions, Vitoc directly beneficially owned 820,921 shares of MAIA common stock. The filing also notes 210,100 shares beneficially owned by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest. The weighted average disclosure indicates the 1,800-share purchase was executed in multiple trades within a narrow price range between $0.9128 and $0.9235.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Vitoc Vlad

(Last) (First) (Middle)
444 WEST LAKE STREET,

(Street)
CHICAGO IL 60606

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/21/2025 P 1,800 A $0.92(1) 810,921 D
Common Stock 11/24/2025 P 10,000 A $0.9891 820,921 D
Common Stock 210,100 I See Footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9128 to $0.9235, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
2. These securities are beneficially owned by Mr. Vitoc's spouse. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
/s/ Vlad Vitoc 11/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MAIA (MAIA) report in this Form 4?

The Form 4 reports that Vlad Vitoc, MAIA Biotechnology's Chief Executive Officer, Director and 10% owner, purchased 1,800 shares of common stock on 11/21/2025 and 10,000 shares on 11/24/2025.

At what prices did the MAIA CEO purchase common stock in November 2025?

On 11/21/2025, he bought 1,800 shares at a weighted average price of $0.92 per share. On 11/24/2025, he purchased 10,000 shares at $0.9891 per share.

How many MAIA shares does Vlad Vitoc beneficially own after these transactions?

After the reported transactions, Vlad Vitoc directly beneficially owned 820,921 shares of MAIA common stock. The form also lists 210,100 shares beneficially owned by his spouse.

What does the weighted average price disclosure mean in the MAIA Form 4?

The filing states that the $0.92 price is a weighted average for the 1,800 shares bought on 11/21/2025, executed in multiple trades at prices ranging from $0.9128 to $0.9235, inclusive.

How are the MAIA shares held by the CEO's spouse treated in this Form 4?

The Form 4 notes that 210,100 shares are beneficially owned by Mr. Vitoc's spouse and states that he disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Is this MAIA Form 4 filed by one or multiple reporting persons?

The Form 4 is indicated as being filed by one reporting person, namely Vlad Vitoc.
MAIA Biotechnology Inc.

NYSE:MAIA

MAIA Rankings

MAIA Latest News

MAIA Latest SEC Filings

MAIA Stock Data

39.25M
29.93M
21.43%
6.93%
1.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
CHICAGO